Skip to main content
Clinical Trials/NCT02901015
NCT02901015
Completed
Not Applicable

Evaluation and Validation of Social Cognition Battery to Characterize Schizophrenic Patients Functioning (EVACO)

Versailles Hospital8 sites in 1 country173 target enrollmentApril 2013
ConditionsSchizophrenia

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Schizophrenia
Sponsor
Versailles Hospital
Enrollment
173
Locations
8
Primary Endpoint
Change in cognitive skills
Status
Completed
Last Updated
8 years ago

Overview

Brief Summary

Interventional, multicenter, and longitudinal study, of a cohort of patients with schizophrenia, evaluated on social cognition, neurocognition, symptoms, functioning with 12 months interval.

Detailed Description

The main objective is evaluation and validation of social cognition battery, characterizing the psychometric properties (validity, sensitivity to change) measures in a cohort of schizophrenic patients. Other objective is to demonstrate that the various components operating at T0 and T12 months of schizophrenic patients, as an external validator, are significantly explained by social cognition performance given the third known factors : neuropsychological, sociodemographic, disease course, and clinical status. Search and model relationships between the measured variables.

Registry
clinicaltrials.gov
Start Date
April 2013
End Date
December 2017
Last Updated
8 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Sponsor
Versailles Hospital
Responsible Party
Principal Investigator
Principal Investigator

Eric BRUNET

Investigator coordinator

Versailles Hospital

Eligibility Criteria

Inclusion Criteria

  • Schizophrenia or schizoaffective disorder
  • Age \> 18 years and \< 65 years
  • Patient's state allows cognitive and neuropsychological assessment
  • Affiliated to a social security system (beneficiary or legal).
  • Informed consent signature (patients under guardianship may be included with written permission from their legal representative).

Exclusion Criteria

  • Alcohol dependence or current toxic
  • Electroconvulsivotherapy (less than 6 months)
  • Serious head trauma (become unconscious), epilepsy or neurological disorder significant or evolutionary
  • Invalidating and uncorrected visual disorder
  • Invalidating and not paired hearing
  • Actually hospitalized under constraint
  • Patient not able to come to different evaluations, or who plan to change medical care in the following year

Outcomes

Primary Outcomes

Change in cognitive skills

Time Frame: Day 0, Month 12

Change in the aggregates (average) of standardized performance levels : z-scores of Theory of mind (V-COMICS, V-SIR, SPEX), z-scores of empathy (QCAE), z-scores of facial affect recognition (TREF), z-scores of metacognition (V-COMICS meta), Intelligence quotient (WAIS-III), z-scores of treatment speed, z-scores of memory spans, z-scores of verbal memory, z-scores of visual memory, z-scores of attention/vigilance, z-scores of divided attention, z-scores of executive functions.

Secondary Outcomes

  • Change in Functioning(Day 0, Month 12)
  • Change in Psychotic symptoms(Day 0, Month 12)

Study Sites (8)

Loading locations...

Similar Trials